Navigation Links
Lithium of No Benefit in ALS, Study Finds
Date:8/11/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Aug. 11 (HealthDay News) -- A new study appears to dash hopes that the psychiatric drug lithium can benefit patients with amyotrophic lateral sclerosis (ALS).

The investigation involving 171 people with ALS was stopped early, in November 2009, because of high dropout rates from death, side effects or because patients thought the drug was ineffective.

ALS -- sometimes called Lou Gehrig's disease after the N.Y. Yankee who died of the condition -- is a progressive nervous system disorder that causes weakness in muscles, including those controlling breathing and swallowing. Median survival is three years, and only one drug -- riluzole -- is approved for ALS treatment in the United States.

Interest in lithium, which is often used to treat bipolar disorder, increased after a small Italian study was published two years ago, suggesting a beneficial effect for ALS patients, said Dr. Adriano Chio, an associate professor of neurology at the University of Torino, Italy. In that study, lithium was thought to have prolonged survival of 16 ALS patients, Chio said.

How might lithium have helped?

"Lithium could have an effect on one of the mechanisms supposedly related to the motor neuron degeneration in ALS, the accumulation of pathological proteins in the neuron," said Chio, who led the new study, noting subsequent research has not confirmed this effect.

In the new study, published in the Aug. 17 issue of Neurology, the drop-out rate, at 68 percent, was two times higher than the drop-out rate reported by previous trials, Chio said.

All participants received lithium, but in two different doses, and the drug was not well-tolerated by either group. Patients died or lost their autonomy at the same rate in both groups.

In an editorial accompanying the study, Dr. Carmel Armon of Tufts University said one limitation of the Chio study, which Chio acknowledges, is that it didn't use a true placebo, but rather different doses. Other ongoing studies that are comparing the active drug to placebo may give the definitive answers, Armon said.

"This study [by Chio] shows there are toxic doses of lithium," said Lucie Bruijn, chief scientist for the ALS Association in Washington, D.C.

"We knew lithium has to be monitored carefully in terms of dose," Bruijn said. "What's shown here [in the new study] is a toxic level in some cases and not a strong benefit."

Even at what was termed "subtherapeutic doses," the lithium was poorly tolerated, Chio found. All 71 patients reported at least one adverse event, some as serious as heart disturbance, cerebral hemorrhage or deep vein blood clots.

Chio said two other trials are assessing the effect of lithium in ALS, but he doubts any positive effect of lithium will be shown.

In the future, Chio added, stem cell therapy may prove useful for ALS.

More information

To learn more about ALS, visit the ALS Association.

SOURCES: Adriano Chio, M.D., associate professor, neurology, First Faculty of Medicine, University of Torino, Italy; Lucie Bruijn, Ph.D., chief scientist, ALS Association, Washington, D.C.; Aug. 17, 2010, Neurology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. No Evidence That Lithium Helps in ALS
2. 30 million women to benefit from health reform law
3. Researchers study benefits of white button mushrooms
4. Study finds patients benefit from thorough discussion of recommended operations
5. Society of Interventional Radiology advances global definition of specialty, benefits patients
6. Social Security Disability Benefits Can Be Crucial to Surviving With Spinal Cord Injury, Allsup Reports
7. Advocate Health Care Reports $462 Million in Community Benefits
8. Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities
9. Mulago Positive Women's Network Announce Their "BONO" Bracelet Fundraiser to Benefit HIV+ Women in Uganda
10. Intensively lowering glucose: Possible benefits must be weighed against risks
11. Examining risks and benefits of alcohol consumption
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lithium of No Benefit in ALS, Study Finds
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: